Nicholas Adlard

Efficacy classification of modern therapies in multiple sclerosis

Imtiaz A. Samjoo, Evelyn Worthington, Christopher Drudge et al. · Journal of Comparative Effectiveness Research · 2021 · 118 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +10

Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis

Imtiaz A. Samjoo, Evelyn Worthington, Christopher Drudge et al. · Journal of Comparative Effectiveness Research · 2020 · 69 citations · Full text

Medicine, Neurology, Pharmacotherapy +12

Current issues and future research priorities for health economic modelling across the full continuum of Alzheimer's disease

Anders Gustavsson, Colin Green, Roy Jones et al. · Alzheimer s & Dementia · 2017 · 44 citations

Pharmacy, Health Policy, Pharmacoeconomics +17

A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in Multiple Sclerosis

Catherine Bottomley, Andrew Lloyd, Bennett Gary et al. · Journal of Medical Economics · 2017 · 32 citations

Pharmacy, Neurology, Decision Analysis +15

Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England

M. Maruszczak, Stephen Montgomery, Matthew Griffiths et al. · Journal of Medical Economics · 2015 · 29 citations

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17